Home › Compare › CGFEF vs ABBV
CGFEF yields 166666.67% · ABBV yields 3.06%● Live data
📍 CGFEF pulled ahead of the other in Year 1
Combined, CGFEF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CGFEF + ABBV for your $10,000?
CF Energy Corp. operates as an integrated energy provider and natural gas distribution company in the People's Republic of China. The company operates through Gas Distribution Utility, Integrated Smart Energy, and Smart Mobility segments. It distributes natural gas to industrial, commercial, and residential users; offers natural gas pipeline installation and connection services; and operates two natural gas refueling stations in Sanya city, Hainan Province and Changsha city, Hunan Province that provide refueling services for vehicles, such as household cars, taxicabs, buses, and trucks. The company also transports natural gas through its 2.0 kilometers of pipeline; and develops the Haitang Bay integrated smart energy and the Meishan integrated district energy distribution projects, which uses various clean energy sources, including solar, hydro, electricity, and natural gas to supply cooling, heating, as well as hot water. In addition, it provides electric vehicle battery swap services; construction and warehousing; and charity services. The company was formerly known as Changfeng Energy Inc. and changed its name to CF Energy Corp. CF Energy Corp. was founded in 1995 and is headquartered in Markham, Canada.
Full CGFEF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.